Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
- Sponsor:
- SWOG
- Sponsor Study ID:
- S2303
- CTO #:
- 104136
- NCT Number:
- NCT06203600
- Phase:
- II/III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Esophagus
- Study Objectives:
- To compare health-related quality of life (HRQOL) by treatment arm at 8 weeks after randomization, measured using the Functional Assessment of Cancer Therapy Gastric (FACT-Ga) Trial Outcome Index.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Dincman, Toros, at dincmant@musc.edu .
- Study Coordinator, Concepcion, Holly, at concepch@musc.edu .
-
Ralph H. Johnson VAMC
- Study Coordinator, Jeter, Kathy, at katherine.jeter2@va.gov .
Trial opened at the following institutions:
Ralph H. Johnson VAMC, Medical University of South Carolina